よむ、つかう、まなぶ。
参考資料14 高齢者がん医療Ｑ＆Ａ総論（厚生労働科学研究「高齢者がん診療指針策定に必要な基盤整備に関する研究」） (113 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_28073.html |
| 出典情報 | がん対策推進協議会（第82回 9／20）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
文献
1)
Evidence-Based Management strategies for oral complication from cancer treatment.
http://www.mascc.org/assets/documents/Oral_Care-SummaryOral_Complications_Systematic_Reviews.pdf.
2)
厚生労働省医政局歯科保健課. 平成28年歯科疾患実態調査.
3)
Ripamonti CI et al. Decreased occurrence of osteonecrosis of the jaw after implementation
of dental preventive measures in solid tumour patients with bone metastases treated with
bisphosphonates：the experience of the National Cancer Institute of Milan. Ann Oncol.
2009；20：137-145
4)
Kyrgidis A et al. Bisphosphonate-related osteonecrosis of the jaws： a case-control study of
risk factors in breast cancer patients. J Clin Oncol.2008；26：4634-4638
5)
Van Poznak C et al. American Society of Clinical Oncology executive summaryof the
clinical practice guideline update on the role of bone-modifying agents in metastatic
breastcancer. J Clin Oncol. 2011；29：1221-1227
6)
Ruggiero SL et al. American Association of Oral and Maxillofacial Surgeons position paper
on bisphosphonate-related osteonecrosis of the jaws： 2009 update. J Oral Maxillofac
Surg. 2009；67：2-12
7)
顎骨壊死検討委員会. 骨吸収抑制薬関連顎骨壊死の病態と管理:顎骨壊死検討委員会ポジション
ペーパー2016.
8)
Stopeck AT et al. Denosumab compared with zoledronic acid for the treatmentof bone
metastases in patients with advanced breast cancer: a randomized,double-blind study.
J Clin Oncol. 2010；28：5132-5139
9)
Fizazi K et al. Denosumab versus zoledronic acid for treatment of bone metastases in
men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet.
2011;377:813-822
10) Henry DH et al. Randomized, double-blind study of denosumab versus zoledronic acid in
the treatment of bone metastases in patients with advanced cancer (excluding breast and
prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125-1132
11) Lipton A et al. Superiority of denosumab to zoledronic acid for prevention of skeletalrelated events: a combined analysis of 3 pivotal, randomised,
phase 3 trials. Eur J
Cancer. 2012;48:3082-3092.
12) de Molon RS et al. OPG-Fc but Not Zoledronic Acid Discontinuation Reverses
Osteonecrosis of the Jaws (ONJ) in Mice. J Bone Miner Res. 2015;30:1627-1640
13) Ramírez L et al. New Non-Bisphosphonate Drugs that Produce Osteonecrosis of the Jaws.
Oral Health Prev Dent. 2015;13:385-393
14) Matsuo S et al. Revised equations for estimated GFR from serum creatinine in
Japan. Am J Kidney Dis. 2009;53:982-992
105
1)
Evidence-Based Management strategies for oral complication from cancer treatment.
http://www.mascc.org/assets/documents/Oral_Care-SummaryOral_Complications_Systematic_Reviews.pdf.
2)
厚生労働省医政局歯科保健課. 平成28年歯科疾患実態調査.
3)
Ripamonti CI et al. Decreased occurrence of osteonecrosis of the jaw after implementation
of dental preventive measures in solid tumour patients with bone metastases treated with
bisphosphonates：the experience of the National Cancer Institute of Milan. Ann Oncol.
2009；20：137-145
4)
Kyrgidis A et al. Bisphosphonate-related osteonecrosis of the jaws： a case-control study of
risk factors in breast cancer patients. J Clin Oncol.2008；26：4634-4638
5)
Van Poznak C et al. American Society of Clinical Oncology executive summaryof the
clinical practice guideline update on the role of bone-modifying agents in metastatic
breastcancer. J Clin Oncol. 2011；29：1221-1227
6)
Ruggiero SL et al. American Association of Oral and Maxillofacial Surgeons position paper
on bisphosphonate-related osteonecrosis of the jaws： 2009 update. J Oral Maxillofac
Surg. 2009；67：2-12
7)
顎骨壊死検討委員会. 骨吸収抑制薬関連顎骨壊死の病態と管理:顎骨壊死検討委員会ポジション
ペーパー2016.
8)
Stopeck AT et al. Denosumab compared with zoledronic acid for the treatmentof bone
metastases in patients with advanced breast cancer: a randomized,double-blind study.
J Clin Oncol. 2010；28：5132-5139
9)
Fizazi K et al. Denosumab versus zoledronic acid for treatment of bone metastases in
men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet.
2011;377:813-822
10) Henry DH et al. Randomized, double-blind study of denosumab versus zoledronic acid in
the treatment of bone metastases in patients with advanced cancer (excluding breast and
prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125-1132
11) Lipton A et al. Superiority of denosumab to zoledronic acid for prevention of skeletalrelated events: a combined analysis of 3 pivotal, randomised,
phase 3 trials. Eur J
Cancer. 2012;48:3082-3092.
12) de Molon RS et al. OPG-Fc but Not Zoledronic Acid Discontinuation Reverses
Osteonecrosis of the Jaws (ONJ) in Mice. J Bone Miner Res. 2015;30:1627-1640
13) Ramírez L et al. New Non-Bisphosphonate Drugs that Produce Osteonecrosis of the Jaws.
Oral Health Prev Dent. 2015;13:385-393
14) Matsuo S et al. Revised equations for estimated GFR from serum creatinine in
Japan. Am J Kidney Dis. 2009;53:982-992
105